Research programme: systemic lupus erythematosus and lupus nephritis therapeutics - EMD Serono/Massachusetts General Hospital
Latest Information Update: 08 Sep 2014
At a glance
- Originator EMD Serono; Massachusetts General Hospital
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Lupus nephritis; Systemic lupus erythematosus
Most Recent Events
- 02 Sep 2014 Early research in Systemic lupus erythematosus in USA (unspecified route)
- 02 Sep 2014 Early research in Lupus nephritis in USA (unspecified route)